Over the last few decades clinical cancer research has developed at accelerating speed, resulting in a tremendous increase of knowledge with regard to tumour biology, hypotheses to interfere with tumour growth and the subsequent development of anticancer therapies. Obviously, the ultimate aim of cancer research is to identify treatment approaches improving overall survival with a good quality of life. Novel anticancer therapies mostly arise from scientifi c insights in preclinical studies, and provided that they have looked promising in vitro and in animal models, at one point they have to be tested in humans. Testing new cancer therapies in patients occurs in diff erent stages, i.e. successively in phase I, phase II and phase III trials.

cancer research, cancer therapies, oncology
J. Verweij (Jaap)
Erasmus University Rotterdam
Erasmus MC Rotterdam, Novartis Pharma BV, Johnson & Johnson Pharmaceutical Research and Development, Cornelis Vrolijk Foundation. Further financial support for publication of this thesis was kindly provided by Amgen BV, AstraZeneca BV, Bayer Schering Pharma BV, Boehringer Ingelheim BV, Erasmus Universteit Rotterdam, Janssen-Cilag BV, the J.E. Jurriaanse Stichting, Eli Lily Nederland BV, Merck Sharp & Dohme BV, Novartis Pharma BV, Pfi zer BV, Roche Nederland BV, Sanofi -Aventis Netherlands BV.
978-90-90-25838-6
hdl.handle.net/1765/22796
Erasmus MC: University Medical Center Rotterdam

Konings, I.R.H.M. (2011, February 4). Early clinical cancer trials: Proof of concept and beyond. Erasmus University Rotterdam. Retrieved from http://hdl.handle.net/1765/22796